Mark R. Kelley
Impact in
- Molecular Biology top 0.5%
- DNA Repair Mechanisms
- RNA modifications and cancer
- Advanced biosensing and bioanalysis techniques
- Epigenetics and DNA Methylation
- DNA and Nucleic Acid Chemistry
- CRISPR and Genetic Engineering
- Mitochondrial Function and Pathology
- Cancer therapeutics and mechanisms
- Oncology top 0.5%
Papers in
-
- DNA Repair Mechanisms 105
- Epigenetics and DNA Methylation 23
- RNA modifications and cancer 22
- CRISPR and Genetic Engineering 19
- Cancer therapeutics and mechanisms 14
- DNA and Nucleic Acid Chemistry 13
- Mitochondrial Function and Pathology 12
- Co-authors
- Melissa L. FishelSimon KiddGianluca TellWalter DeutschMeihua LuoMichael R. VaskoAngela R. EvansMillie M. Georgiadis
- Journals
- Journal of Biological Chemistry (13 papers)Cancer Research (9 papers)Molecular Cancer Therapeutics (9 papers)DNA repair (9 papers)Antioxidants and Redox Signaling (7 papers)
- Partner nations
- United StatesItalyUnited Kingdom
In The Last Decade
Mark R. Kelley
230 papers receiving 12.7k citations
Hit Papers
Peers
Comparison fields: 5 of 139
- Molecular Biology 9.2k
- Oncology 2.9k
- Cancer Research 1.4k
- Physiology 355
- Aging 126
Countries citing papers authored by Mark R. Kelley
This map shows the geographic impact of Mark R. Kelley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Kelley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Kelley more than expected).
Fields of papers citing papers by Mark R. Kelley
This network shows the impact of papers produced by Mark R. Kelley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Kelley. The network helps show where Mark R. Kelley may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark R. Kelley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Chemotherapy-induced enteric neuropathy and gastrointestinal dysfunction: Mechanisms and novel treatments | 2020 | 1 |
| 2 | 2019 | 31 | |
| 3 | 2019 | 16 | |
| 4 | 2017 | 20 | |
| 5 | APE1/Ref-1 knockdown in pancreatic ductal adenocarcinoma – characterizing gene expression changes and identifying novel pathways using single-cell RNA sequencing | 2017 | 0 |
| 6 | Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic | 2017 | 1 |
| 7 | 2016 | 93 | |
| 8 | 2014 | 8 | |
| 9 | Role of the DNA Base Excision Repair Protein, APE1 in Cisplatin, Oxaliplatin, or Carboplatin Induced Sensory Neuropathy | 2014 | 1 |
| 10 | Targeting DNA repair pathways for cancer treatment: what's new? | 2014 | 4 |
| 11 | APE1/Ref-1 redox inhibitor APX3330 modulates choroidal endothelial cells by transcriptional regulation of NF-κB and STAT3 activity | 2013 | 1 |
| 12 | Selective Blocking of APE1/Ref-1 Redox Function by a Novel Compound, APX3330 Inhibits Choroidal Endothelial Cells in vitro and Choroidal Neovascularization in vivo | 2012 | 1 |
| 13 | DNA repair in cancer therapy : molecular targets and clinical applications | 2012 | 35 |
| 14 | 2011 | 99 | |
| 15 | 2011 | 134 | |
| 16 | 2010 | 63 | |
| 17 | 2009 | 96 | |
| 18 | The altered gene profile of human osteosarcoma cell after knock-down of double functional gene apurinic/apyrimidinic endonuclease | 2007 | 2 |
| 19 | 1991 | 28 | |
| 20 | 1989 | 16 |
About Mark R. Kelley
Mark R. Kelley is a scholar working on Molecular Biology, Cancer Research, Physiology, Oncology and Reproductive Medicine, having authored 233 papers that have together received 12.9k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (105 papers), Epigenetics and DNA Methylation (23 papers), RNA modifications and cancer (22 papers), CRISPR and Genetic Engineering (19 papers), Cancer therapeutics and mechanisms (14 papers), DNA and Nucleic Acid Chemistry (13 papers), Mitochondrial Function and Pathology (12 papers) and PARP inhibition in cancer therapy (12 papers). The work is most often cited by research in Molecular Biology (9.2k citations), Oncology (2.9k citations), Cancer Research (1.4k citations), Physiology (355 citations) and Aging (126 citations). Mark R. Kelley has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Melissa L. Fishel, Simon Kidd, Gianluca Tell, Walter Deutsch, Meihua Luo, Michael R. Vasko, Angela R. Evans, Millie M. Georgiadis, Martin L. Smith and Franco Quadrifoglio. Their work appears in journals such as Journal of Biological Chemistry, Cancer Research, Molecular Cancer Therapeutics, DNA repair and Antioxidants and Redox Signaling.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.